Neuroscience & Stroke Education Series: New Drugs in Alzheimer's Disease - Beta Amyloid Antibodies and Beyond Recorded Session
This session is part of the Neuroscience & Stroke Education Series.
Review all new drugs available for Alzheimer’s disease including their indications for use.
If you attended New Drugs in Alzheimer's Disease - Beta Amyloid Antibodies and Beyond on May 11, 2023, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.
Target Audience
This course is intended for all physicians including generalists, neurologists, intensivists, radiologists, and pathologists, RN's, PA's, NP's, RTT's, and various other members of the health care team.
Learning Objectives
At the end of this session, learners should be able to:
- Compare and contrast available drugs for Alzheimer’s
- Identify appropriate enrollment requirements for each drug trial
- Identify MRI monitoring parameters following infusion
Faculty
Darren Gitelman, MD; Advocate Aurora Health
Eric Maas, MD; Advocate Aurora Health
Paul Vilar, MSN, RN, SCRN; Advocate Aurora Health
Rachael Wade, MHA; Advocate Aurora Health
Amy Campbell, Executive Assistant; Advocate Aurora Health
Disclosure
The following faculty speakers and/or planning committee members have disclosed the following:
Faculty Name | Name of Ineligible Companies | Nature of Relationship |
Darren Gitelman, MD | Danone; Lilly | Advisory board |
The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. All of the relevant financial relationships listed for this individual have been mitigated.
Accreditation Statement
In support of improving patient care, Advocate Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Statement(s)
American Medical Association (AMA)
Advocate Health designates this enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
Advocate Health designates this enduring activity for a maximum of 1.00 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
Available Credit
- 1.00 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 1.00 AttendanceAttendance Credit
- 1.00 Approved AMA PRA Category 1 Credit™
- 1.00 Continuing Nursing Education (CE)Aurora Health Care is an approved provider of continuing nursing education by the Wisconsin Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. 1.00 contact hours have been awarded to this activity by the Wisconsin Nursing Association. To receive contact hours, participants must attend the entire activity.
Price
Click “Take Course” to register for this program.
If you attended New Drugs in Alzheimer's Disease - Beta Amyloid Antibodies and Beyond on May 11, 2023, you will not be able to claim credit again for this course. However, you are welcome to still watch the content.
If you have any questions, please contact the IPCE Office at cme@aah.org